Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells

BMB Rep. 2015 Aug;48(8):461-6. doi: 10.5483/bmbrep.2015.48.8.216.

Abstract

Epigallocatechin gallate (EGCG) and curcumin are well known to naturally-occurring anticancer agents. The aim of this study was to verify the combined beneficial anticancer effects of curcumin and EGCG on PC3 prostate cancer cells, which are resistant to chemotherapy drugs and apoptosis inducers. EGCG showed weaker inhibitory effect on PC3 cell proliferation than two other prostate cancer cell lines, LNCaP and DU145. Co-treatment of curcumin improved antiproliferative effect of EGCG on PC3 cells. The protein expressions of p21 were significantly increased by the co-treatment of EGCG and curcumin, whereas it was not changed by the treatment with each individual compound. Moreover, treatments of EGCG and curcumin arrested both S and G2/M phases of PC3 cells. These results suggest that the enhanced inhibitory effect of EGCG on PC3 cell proliferation by curcumin was mediated by the synergic up-regulation of p21-induced growth arrest and followed cell growth arrest.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Catechin / administration & dosage
  • Catechin / analogs & derivatives*
  • Catechin / pharmacology
  • Cell Cycle Checkpoints / drug effects
  • Cell Division / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Curcumin / administration & dosage
  • Curcumin / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Up-Regulation / drug effects

Substances

  • Catechin
  • epigallocatechin gallate
  • Curcumin